TNFRSF9 and neoplasm: To validate the anti-tumor effect of rhCD137L-MSNs, we compared their ability in enhancing T cell-mediated tumor cytolysis to that of MSNs loaded with anti-CD137 antibodies urelumab and utomilumab, herein referred to as ure-MSNs and uto-MSNs, respectively.